155 completed, 59 terminated, 31 active not recruiting, 17 recruiting. 292 Phase 2, 84 Phase 1, 3 Phase 3.
Follow Revlimid: new trials by email Literature Review of Revlimid trials Research Report on Revlimid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-26 |
| Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-10-07 | 2026-10-21 |
| Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma Elranatamab, Daratumumab, Lenalidomide - Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM) | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 100 | 2025-08-08 | 2026-06-04 |
| Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Epcoritamab - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder | Phase 2 | Recruiting | Reem Karmali | 34 | 2025-07-25 | 2026-07-08 |
| Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant Belantamab Mafodotin, Lenalidomide - Plasma Cell Myeloma | Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 4 | 2024-08-19 | 2026-10-16 |
| Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Multiple Myeloma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 58 | 2024-07-23 | 2026-09-25 |
| Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients. Lenalidomide, Obinutuzumab Injection [Gazyva] - Chronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 1 / Phase 2 | Recruiting | Vitebsk Regional Clinical Cancer Centre | 24 | 2024-05-14 | 2026-08-13 |
| Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Follicular Lymphoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 29 | 2024-01-24 | 2026-08-26 |
| Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant Selinexor, Lenalidomide, Dexamethasone - Multiple Myeloma, Myeloma-Associated Amyloidosis | Phase 2 | Withdrawn | Washington University School of Medicine | 2024-01-05 | 2024-07-10 | |
| Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 100 | 2024-01-04 | 2024-11-18 |
| Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma Daratumumab, Carfilzomib, Lenalidomide - Multiple Myeloma, Primary Plasma Cell Leukemia | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 54 | 2023-10-20 | 2025-04-16 |
| Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment Biospecimen Collection, Computed Tomography, Lenalidomide - Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 227 | 2023-09-26 | 2026-10-28 |
| CURATE.AI Optimized Modulation for Multiple Myeloma Bortezomib, Cyclophosphamide, Dexamethasone - Multiple Myeloma | Phase 2 / Phase 3 | Unknown | National University Hospital, Singapore | 20 | 2023-09-10 | 2023-09-06 |
| Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 50 | 2023-08-10 | 2026-10-26 |
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Maplirpacept, Tafasitamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 6 | 2023-08-04 | 2025-09-05 |
| Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma Biopsy, Biospecimen Collection, Carboplatin - Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Active not recruiting | David Bond, MD | 37 | 2023-06-29 | 2026-07-20 |
| Elimination of Minimal Residual Disease After Transplant Dexamethasone, Isatuximab, Lenalidomide - Multiple Myeloma | Phase 2 | Active not recruiting | Medical College of Wisconsin | 30 | 2023-06-26 | 2026-10-20 |
| A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide IMM0306, Lenalidomide capsule - B-cell Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Unknown | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 102 | 2023-05-01 | 2023-05-24 |
| A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL Mosunetuzumab, Polatuzumab vedotin, Tafasitamab - Hodgkin Lymphoma, B-Cell Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 36 | 2023-04-28 | 2026-09-18 |
| Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial Bone Marrow Aspiration and Biopsy, Carfilzomib, Computed Tomography - ISS Stage III Plasma Cell Myeloma, Multiple Myeloma | Phase 2 | Active not recruiting | Mayo Clinic | 17 | 2022-09-22 | 2026-05-13 |
Showing 20 of 292. Sign in to see all of them.
Multiple Myeloma (103) · Leukemia, Lymphocytic, Chronic, B-Cell (37) · Lymphoma, Large B-Cell, Diffuse (23) · Lymphoma, Follicular (21) · Lymphoma, Mantle-Cell (19) · Myelodysplastic Syndromes (19) · Lymphoma (15) · Lymphoma, Non-Hodgkin (14) · Recurrence (14) · Leukemia (12) · Lymphoma, B-Cell, Marginal Zone (12) · Neoplasms, Plasma Cell (11) · Leukemia, Myeloid, Acute (10) · Hodgkin Disease (9) · Lymphoma, B-Cell (9)
M.D. Anderson Cancer Center (38) · National Cancer Institute (NCI) (23) · Mayo Clinic (12) · Celgene (10) · Weill Medical College of Cornell University (7) · Celgene Corporation (6) · Dana-Farber Cancer Institute (6) · Washington University School of Medicine (6) · City of Hope Medical Center (5) · SCRI Development Innovations, LLC (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5) · Fred Hutchinson Cancer Center (4) · University Health Network, Toronto (4) · University of Nebraska (4) · Arbeitsgemeinschaft medikamentoese Tumortherapie (3)
United States (215) · Germany (16) · Canada (15) · Italy (15) · France (12) · China (10) · Spain (8) · United Kingdom (8) · Australia (6) · Belgium (5) · Sweden (5) · Austria (4) · Denmark (4) · Israel (3) · Japan (3)
Ravi Vij, M.D. (4) · Bruno Carneiro de Medeiros (3) · Alessandra Ferrajoli (2) · Alessandra Ferrajoli, MD,BS (2) · Antonio Palumbo, MD (2) · Felicitas Hitz, MD (2) · Grzegorz S Nowakowski (2) · James R Berenson, MD (2) · Lei Zhang, MD (2) · Leona Holmberg (2) · Loretta J Nastoupil (2) · Michael Choi, MD (2) · Shaji Kumar (2) · Sonali Smith (2)
PMID 29358183, PMID 39319495, PMID 23834234, PMID 26181891, PMID 35549810, PMID 35952327, PMID 38652812, PMID 18334676, PMID 18824593, PMID 19118065, PMID 19182205, PMID 20651074, PMID 20724537, PMID 21051557, PMID 21228334, PMID 21504290, PMID 21551228, PMID 21596852, PMID 21719884, PMID 21725050, PMID 21812019, PMID 21937701, PMID 22033493, PMID 22517904, PMID 22936658, PMID 22983583, PMID 23242596, PMID 23592273, PMID 23648434, PMID 23731832, PMID 23801633, PMID 24004667, PMID 24019544, PMID 24030098, PMID 24244261, PMID 24244687, PMID 24606326, PMID 24819395, PMID 24914044, PMID 25052451, PMID 25283471, PMID 25439689, PMID 25540937, PMID 25837499, PMID 25921098, PMID 26088933, PMID 26250576, PMID 26284823, PMID 26327694, PMID 26331432
P30CA015083 (7), 2009 (6), 2008 (5), U10CA180821 (5), U10CA180888 (4), P30CA014599 (3), P30CA015704 (3), P30CA016672 (3), P30CA036727 (3), U10CA031946 (3), U10CA032102 (3), 2015 (2), 2019 (2), N01CM00071 (2), N01CM62201 (2)